Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer

Next Previous
Search
Trial Profile

PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trilaciclib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Myelosuppression; Rectal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PRESERVE 1
  • Sponsors G1 Therapeutics

    • Most Recent Events

    • 04 Jul 2023 This trial has been completed in Poland, according to the European Clinical Trials Database record.
    • 13 Feb 2023 According to a G1 Therapeutics media release, company will host a webcast and conference call at 8:30 am ET today to discuss PRESERVE 1 and Company's ongoing commercial and clinical programs.
    • 13 Feb 2023 According to a G1 Therapeutics media release, company announced topline data and co-primary endpoints data related to severe neutropenia with statistical significance data of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top